Astellas' Xospata for FLT3-Mutated AML Garners European Commission Approval

Oct 31, 2019

|

NEW YORK – The European Commission has approved gilteritinib (Astellas' Xospata) as a treatment for adult acute myeloid leukemia who have relapsed or refractory disease characterized by FLT3 mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Astellas' Xospata for FLT3-Mutated AML Garners European Commission Approval

To read the full story....

Breaking News

T Cell Assessment in Primary Melanomas Can Help Predict Metastatic Recurrence

Genetic Testing Challenges in Oncology: Patient Told Genetic Test was Negative Turns out to be MAP Carrier

FDA Accepts Bridge Biotherapeutics' Investigational New Drug Application for Lung Cancer Drug

Myriad Genetics Files for FDA Approval of BRACAnalysis CDx for Lynparza in Prostate Cancer

JP Morgan Healthcare, Day 4: Five Prime Therapeutics and Gritstone Oncology

NTRK Fusion Drug Not Cost Effective for Tumor-Agnostic Use, UK's NICE Suggest

What's Popular?

Myriad Genetics Files for FDA Approval of BRACAnalysis CDx for Lynparza in Prostate Cancer

FDA Accepts Bridge Biotherapeutics' Investigational New Drug Application for Lung Cancer Drug

In Precision Oncology, Drugs Coming to Market Based on Smaller, Early-Phase, Single-Arm Trials

JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera

FDA Accepts Clovis Oncology's Supplemental Drug Application for Rubraca in Advanced Prostate Cancer

Sponsorships